Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)

BioAffinity's CyPath(r), Lung Test is a cost-effective and non-invasive tool that aids in early detection of lung cancer. It is one of the most deadly forms of cancer. It is important to be diagnosed early, before the cancer spreads. CyPath(r), Lung uses flow cytometry to profile approximately 20 million cells from an average sputum sample within 20 minutes. BioAffinity generated gross proceeds of $15.6million from its September 2022 Initial Public Offering (IPO). This included the issuance and exercise of certain legacy warrants, as well the issue of share/warrant unit shares. bioAffinity Technologies, Inc. is a non-invasive diagnostic test company based in San Antonio, Texas. It also develops targeted cancer therapies. CyPath(r), Lung is the company's first product. It uses flow cytometry to help in early detection of lung cancer. This test is in the early stages of commercialization. Pre-clinical research is underway to develop targeted therapies for cancer at the cellular level. Argus Research, headquartered in NYC (URL), is a top independent equity research company (est. 1934). 1934), providing quantitative and fundamental research coverage on over 1,600 companies in all 11 sectors. Argus recently announced that it will provide a sponsored research solution to small and mid-cap companies who are interested in coverage. As part of a Sponsored Research Agreement between Argus Research and the company, Argus Research Co. received a flat-fee from the company mentioned in this report. Argus Research has not received compensation for any part of the assessment. SOURCE Argus Research